Ethics Statement

This article is a narrative review and does not involve human subjects, patient data, or clinical interventions. Therefore, ethical approval and informed consent were not required.

Exosomes in Skin Rejuvenation

Mesenchymal Stem Cell Secretome/Conditioned Medium

Platelet-Rich Plasma (PRP)

Comparative Synthesis

Regulatory considerations

PRP is widely permitted as a minimally manipulated autologous biologic. Exosomes and secretome face stricter biologic regulations [5,13].

To support comparative interpretation, two summary tables were constructed. Table 1 outlines the biological characteristics, mechanisms, evidence strength, and limitations of PRP, MSC secretome, and exosomes. The table clearly demonstrates that PRP currently has the strongest clinical and histologic evidence, whereas secretome offers broad reparative signaling, and exosomes provide advanced molecular precision but remain the least standardized. Table 2 synthesizes practical recommendations for clinical integration across various procedural contexts, including microneedling, fractional resurfacing, and recovery optimization.

	Table 1: Comparative summary of PRP, MSC secretome, and exosomes in skin rejuvenation.
	Table 2: Clinical integration and practical recommendations.

Exosomes: Mechanistic Sophistication, Early-Stage Translation

Exosomes embody the most advanced biological design, functioning as naturally targeted delivery systems for microRNAs, proteins, and lipids. Their ability to modulate oxidative stress pathways, downregulate MMPs, suppress NF-κB, and enhance type I collagen synthesis positions them as elegant molecular regulators of skin aging [1–4]. However, clinical application remains at an early phase, with current evidence largely limited to small studies and adjunctive procedural use [4,5]. Major translational barriers include variability in manufacturing, the absence of standardized potency assays, and stringent regulatory oversight. Without GMP-certified exosomal platforms and long-term safety data, their role remains primarily experimental.

MSC Secretome: Broad, Physiologic Repair Signaling

Secretome contains a diverse array of soluble factors and extracellular vesicles that more closely mimic the native paracrine activity of MSCs. This breadth of signaling—spanning angiogenesis, antioxidant pathways, ECM remodeling, and immunomodulation—offers a physiologic and multi-modal regenerative approach [6–9]. Early clinical results show meaningful improvements in elasticity, hydration, and recovery post-resurfacing. Secretome has advantages over exosomes in manufacturing scalability and biological robustness, yet it remains limited by donor variability, regulatory complexities, and non-standardized assays.

PRP: Clinically Established and Translationally Mature

PRP remains the benchmark among regenerative biologics. Its mechanisms—rooted in platelet-derived growth factor release—are highly aligned with phases of wound healing and dermal repair [10–12]. Randomized controlled trials consistently demonstrate improvements in fine lines, periorbital changes, and overall texture [10–12,14,15], while histologic evidence confirms enhanced collagen density and dermal architecture. Unlike exosomes and secretome, PRP benefits from strong regulatory acceptance, minimal immunogenicity, affordability, and widespread accessibility. Its limitations, centered on preparation variability, are comparatively minor and manageable.

Current evidence establishes a clear functional hierarchy among regenerative biologics for aging skin. PRP remains the most reliable and clinically validated modality, supported by controlled trials, histologic data, and predictable safety. MSC secretome represents an intermediate option with broad reparative signaling and promising early clinical results, yet still limited by variability and the need for stronger standardization. Exosomes, while mechanistically the most advanced, remain the least standardized and least supported by high-quality clinical data, placing them at the earliest stage of translational readiness.

In practice, the most consistent outcomes arise from procedure-integrated applications rather than standalone biologics. PRP combined with microneedling reliably enhances collagen induction. Secretome or exosomes applied after laser resurfacing accelerate recovery and improve dermal remodeling. Increasingly, clinicians use multi-modal, tailored combinations to achieve synergistic benefits aligned with individual patient needs and aging profiles.

The comparative tables reinforce the therapeutic hierarchy observed in current literature. As illustrated in Table 1, PRP remains the most evidence-supported biologic, driven by reproducible growth-factor stimulation and strong safety. Secretome occupies an intermediate position with wide-ranging reparative signals, while exosomes—although mechanistically sophisticated—are constrained by standardization and regulatory gaps. Table 2 highlights that optimal outcomes arise from procedure-integrated approaches. PRP reliably enhances collagen induction with microneedling, whereas secretome and exosomes are superior as post-resurfacing modulators, accelerating healing and improving overall rejuvenation. These tables emphasize that biologics should be selected based on therapeutic precision, patient needs, and procedural context.

Remaining Gaps and Future Directions

Despite promising developments, regenerative biologics cannot advance without resolving several critical gaps. The field urgently requires standardized potency assays, direct comparative trials, and robust long-term safety data, particularly for allogeneic products. Clear dose–response parameters and protocol standardization are also needed to minimize clinical variability. Future studies must incorporate biomarker-based, imaging, and histologic endpoints to objectively quantify outcomes. Only through these scientific refinements can regenerative therapies transition from emerging innovations to reliable, evidence-driven dermatologic interventions. Advancements in GMP manufacturing, machine-learning–assisted phenotyping, and personalized biologic formulations may further refine regenerative dermatology.